Understanding Growth Hormone Therapy and Injection Technique
The most critical nursing intervention for a child receiving growth hormone therapy is rotating injection sites daily. This practice directly prevents
lipoatrophy, a localized and irreversible loss of subcutaneous fat tissue, which is a significant adverse effect of recombinant human growth hormone (rhGH) administration.
Pathophysiology and Clinical Significance of Lipoatrophy
Lipoatrophy is characterized by a well-demarcated depression in the skin resulting from damage to subcutaneous adipocytes. While the exact mechanism is not fully understood, it has been linked to the formation of neutralizing antibodies against the growth hormone preparation
[1]. Critically, repeated injections into the same site are a common contributing factor to this complication. A 2021 observation noted localized lipoatrophy in
14.5% of patients receiving daily rhGH, underscoring that this is not a rare event
[1]. Because the damage to the fat tissue is irreversible, prevention through consistent site rotation is paramount. The development of long-acting growth hormone (LAGH) formulations, such as weekly somatrogon, aims to improve compliance by reducing injection frequency, but the principle of rotating the injection site with each dose remains essential to minimize local tissue trauma [3,4].
Analyzing the Incorrect Options
-
Option 1: Administer the injection in the morning before breakfast. Growth hormone is typically administered as a subcutaneous injection in the evening to mimic the body's natural pulsatile secretion pattern, which predominantly occurs during sleep. There is no evidence from the provided sources to suggest that morning administration maximizes absorption; rather, clinical practice standardizes evening dosing.
-
Option 3: Monitor blood glucose levels only during the first week of treatment. Growth hormone antagonizes insulin action and can cause hyperglycemia. Metabolic monitoring, including blood glucose and
insulin-like growth factor-1 (IGF-1) levels, is a continuous safety requirement throughout the course of treatment, not just during the first week [2,3]. Real-world studies on somatrogon specifically track metabolic impact over a follow-up period of up to 24 months .
-
Option 4: Encourage the child to increase calcium intake to prevent bone demineralization. Growth hormone therapy promotes linear bone growth and increases bone mineral density; it does not cause bone demineralization. While adequate calcium and vitamin D are important for all children, this is not a specific nursing intervention required to counteract a side effect of the therapy itself.
References (research sources)